The following is a summary of the Myomo, Inc. (MYO) Q4 2023 Earnings Call Transcript:

Financial Performance:

• Myomo achieved a successful growth in product revenues by 20% year-over-year, with a reduction in advertising expenses by almost $1 million.

• A total revenue of $19 million was reported in 2023, marking an 11-year streak in revenue growth for the company.

• Cash use in operations was significantly cut by nearly 40% to $6.2 million for 2023, down from over $10 million the previous year.

• For Q4, Myomo registered revenue of $4.8 million, an 18% growth from the prior year due to a 6% increase in revenue units and a higher ASP.

• Q4 gross margin stood at 65.3%, a marginal increase from the previous year attributed majorly to higher ASP.

Business Progress:

• Myomo's MyoPro product line has secured updated pricing from CMS, effective from April 2024, which will expand business prospects under Medicare Part B health insurance.

• There is a strong pipeline with over 1,000 patients and a backlog of 230 units, which represents a 40% growth compared to 2022.

• Myomo is planning to increase its emphasis on O&P channel in 2024 and aims to augment facilities to accommodate demand.

• The company sees an opportunity for business expansion in Germany and possibly China due to favourable market conditions.

• Myomo intends to achieve operating cash flow breakeven on a quarterly basis by Q4 2024.

More details: Myomo IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.